Stefanie Flückiger-Mangual, Chief Executive Officer, is one of TOLREMO’s scientific founders and an expert in drug resistance in cancer therapy. She is a biomedical scientist and biochemist by training (University of Fribourg and ETH Zurich, Switzerland) and holds a Ph.D. in Molecular and Translational Biomedicine from ETH Zurich. She led the team of scientists who discovered novel molecular mechanisms that can be exploited to prevent the development of non-genetic resistance to cancer therapies.

Alessandra Cesano, MD, PhD, is the consulting CMO at TOLREMO Therapeutics. She is a board-certified oncologist with extensive experience as a CMO at biotechnology companies, including ESSA Pharma, NanoString, Cleave Biosciences and Nodality, where she also acted as COO. Additionally, she held various management positions at Amgen, Biogen Idec, and SmithKline Beecham Pharmaceuticals, where she helped advance various oncology drugs through late-stage development and FDA approvals. Early in her professional career, Dr. Cesano spent 12 years conducting research in tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center connected with the University of Pennsylvania. Dr. Cesano received an MD summa cum laude and a PhD in Tumor Immunology from the University of Turin. She is an author on over 140 publications.

Jessica Corson joined Tolremo in 2023 as our Chief Business Officer. Jessica has over 20 years of strategic and operational experience within the biotech industry. Most recently, she was Vice President of Corporate Strategy, Business Development and Alliance Management at Mirati Therapeutics, where she oversaw and executed the company’s strategy for external collaborations. Prior to joining Mirati in 2013, Jessica held roles of increasing responsibility in Business Development at Amylin Pharmaceuticals, from 2006 until the company’s sale to Bristol-Myers Squibb in 2012. Jessica serves on the board of directors at RS Oncology, a clinical-stage biotech company. She holds an M.B.A. from the UCLA Anderson School of Management and a B.S. in Biology from the University of California, San Diego.

Claudia Escher is Chief Operating Officer at TOLREMO. She joins from Biognosys, a Swiss company focusing on the development and application of mass spectrometry proteomics. As COO she was heading the contract research department and responsible for the commercial application of next generation proteomics for the pharmaceutical and biotechnology industry. Claudia graduated at the ETH Zürich in Environmental Sciences with a focus on biology. She holds a PhD in biochemistry from the University of Basel, Department of Neurobiology and the University of Applied Sciences Northwestern Switzerland for her work in biomarker discovery for muscular dystrophies using mass spectrometry.